Molecular modelling of the 5-hydroxytryptamine receptors

Receptors and Channels

Volumn 6, Issue 4, 1999, Pages 317-335

  Wishart, G ^a   Bremner, D H ^b   Sturrock, K R ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Molecular models; Receptors; Review

Indexed keywords

BACTERIORHODOPSIN; CARBON; CELL RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; SEROTONIN RECEPTOR;

ACCURACY; DNA TEMPLATE; DRUG DESIGN; ELECTRON; EXPERIMENTATION; HUMAN; LIGAND BINDING; MOLECULAR MODEL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR AFFINITY; REVIEW;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BACTERIORHODOPSINS; GTP-BINDING PROTEINS; HUMANS; INTERNET; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, SEROTONIN; RHODOPSIN; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032800309     PISSN: 10606823     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Adham N Tamm JA Salon JA Vaysse J-J Weinshank RL and Branchek TA (1994) Neuropharmacology 33 387-391.
2. Agarwal A (1993) PhD Thesis, University Georgia, Athens, USA.
3. Almaula N Ebersole BJ Zhang D Weinstein H and Sealfon SC (1996) J Biol Chem 271 14672-14675.
4. Almaula N Ebersole BJ Ballesteros JA Weinstein H and Sealfon SC (1996a) Mol Pharmacol 50 34-42.
5. Applebury ML and Hargrave PA (1986) Vision Res 26 1881-1895.
6. Attwood TK and Findlay JBC (1993) Protein Eng 6 167-176.
7. Attwood TK and Findlay JBC (1994) Protein Eng 7 195-203.
8. Baldwin JM (1993) EMBO J 12 1693-1703.
9. Baldwin JM Schertler GFX and Unger VM (1997) J Mol Biol 272 144-164.
10. Ballesteros JA and Weinstein H (1995) "Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors" in Methods in Neurosciences (Ed Sealfon S C) Vol 25 pp 366-428 Academic Press.
11. Bikker JA Trumpp-Kallmeyer S and Humblet C (1998) J Med Chem 41 2911-2927.
12. Blaney FE and Tennant M (1996) "Computational tools and results in the construction of G protein-coupled receptor models"; in Membrane Protein Models (Ed Findlay JBC) pp 161-176 Bios Scientific Publishing.
13. Boess FG and Martin IL (1994) Neuropharmacology 33 275-317.
14. Boess FG Monsima Jr FJ Meyer V Zwingelstein C and Sleight AJ (1997) Mol Pharmacol 52 515-523.
15. Branchek T (1993) Med Chem Res 3 287-296.
16. Bremner DH Ringan NS and Wishart G (1997) Eur J Med Chem 32 59-69.
17. Bromidge SM Duckworth M Forbes IT Ham P King FD Thewlis KM Blaney FE Naylor CB Blackburn TP Kennett MD Wood MD and Clarke SE (1997) J Med Chem 40 3494-3496.
18. Bromidge SM Dabbs S Davies DT Duckworth DM Forbes IT Ham P Jones GE King FD Saunders DV Starr S Thewlis KM Wyman PA Blaney FE Naylor CB Bailey F Blackburn Holland V Kennett GA Riley GJ and Wood MD (1998) J Med Chem 41 1598-1612.
19. Buck F Meyerhof W Werr H and Richter D (1991) Biochem Biophys Res Comm 178 1421-1428.
20. Chanda PK Minchin MCW Davis AR Greenberg L Reilly Y McGregor WH Bhat R Lubeck MD Mizutani S and Hung PP (1993) Mol Pharmacol 43 516-520.
21. Choudhary MS Craigo S and Roth BL (1992) Mol Pharmacol 42 627-633.
22. Choudhary MS Craigo S and Roth BL (1993) Mol Pharmacol 43 755-761.
23. Choudhary MS Sachs N Uluer A Glennon RA Westkaemper RB and Roth BL (1995) Mol Pharmacol 41 450-457.
24. Dahl SG Edvardsen Ø and Sylte I (1990) Eur J Pharmacol 183 14.
25. Dahl SG Edvardsen Ø and Sylte I (1991) Proc Natl Acad Sci USA 88 8111-8115.
26. Dahl SG Edvardsen Ø and Sylte I (1991a) Therapie 46 453-459.
27. Davies A Schertler GFX Gowen BE and Saibil HR (1996) J Struct Biol 117 36-44.
28. Dijkstra GDH Tulp MThM Hermkens PHH van Maarseveen JH Scheeren HW and Kruse CG (1993) Recl Trav Chim Pays-Bas 112 131-136.
29. Dohlman HG Caron MG DeBlasi A Frielle T and Lefkowitz RJ (1990) Biochemistry 29 2335-2342.
30. Donnelly D Overington JP Ruffle SV Nugent JHA and Blundell TL (1993) Protein Science 2 55-70.
31. Donnelly D and Cogdell RJ (1993) Protein Eng 6 629-635.
32. Donnelly D and Findlay JBC (1994) Current Opinion in Structural Biology 4 582-589.
33. Donnelly D Findlay JBC and Blundell TL (1994) Receptors and Channels 2 61 -78.
34. Dratz EA and Hargrave PA (1983) Trends Biochem Sci 8 128-131.
35. Edvardsen Ø Sylte I and Dahl SG (1992) Mol Brain Res 14 166-178.
36. Edvardsen Ø and Kristiansen K (1997) 7TM 6.
37. Edvardsen Ø and Kristiansen K (1997a) Trends Biochem Sci 22 226-227.
38. Findlay JBC and Pappin DJC (1986) Biochem J 238 625-642.
39. Findlay JBC Donnelly D Bhogal N Hurrell C and Attwood TK (1993) Biochem Soc Trans 21 869-873.
40. Flower DR (1998) 7TM 7.
41. Forbes IT Dabbs S Duckworth DM Ham P Jones GE King FD Saunders DV Blaney FE Naylor CB Baxter GS Blackburn TP Kennett GA and Wood MD (1996) J Med Chem 39 4966-4977.
42. Gaster LM Blaney FE Davies S Duckworth DM Ham P Jenkins S Jennings AJ Joiner GF King FD Muholland KR Wyman PA Hagan JJ Hatcher J Jones BJ Middlemiss DN Price G Riley G Roberts C Routledge C Selkirk J and Slade PD (1998) J Med Chem 41 1218-1235.
43. Gerhardt CC and van Heerikhuizen H (1997) Eur J Pharmacol 334 1-23.
44. Glennon RA and Westkaemper RB (1992) "Serotonin Receptors, 5-HT Ligands and Receptor Modeling"; in Trends in Receptor Research (Eds Angeli P Gulini U and Quaglia W) pp 185-207 Elsevier.
45. Glennon RA and Westkaemper RB (1993) Drug News and Perspectives 6 390-405.
46. Glennon RA Dukat M Westkaemper RB Ismaiel AM Izzarelli DG and Parker EM (1996) Mol Pharmacol 49 198-206.
47. Grigorieff N Ceska TA Downing KH Baldwin JM and Henderson R (1996) J Mol Biol 259 393-421.
48. Guan X-M Peroutka SJ and Kobilka BK (1992) Mol Pharmacol 41 695-698.
49. Hartig PR Adham N Zgombick J Weinshank R and Branchek T (1992) Drug Dev Res 26 215-224.
50. Hartig PR Hoyer D Humphrey PPA and Martin GR (1996) Trends Pharmacol Sci 17 103-105.
51. Hedberg MH Johansson AM Nordvall S Ylimemelä A Li HB Martin AR Hjorth S Unelius L Sundell S and Hacksell U (1995) J Med Chem 38 647-658.
52. Hedberg MH Jansen JM Nordvall G Hjorth S Unelius L and Johansson AM (1996) J Med Chem 39 3491-3502.
53. Hedberg MH Linnanen T Jansen JM Nordvall G Hjorth S Unelius L and Johansson AM (1996a) J Med Chem 39 3503-3513.
54. Henderson R Baldwin JM Ceska TA Zemlin F Beckmann E and Downing KH (1990) J Mol Biol 213 899-929.
55. Henderson R and Schertler GFX (1990) Phil Trans R Soc Lond B 326 379-389.
56. Hibert MF Mir AK and Fozard JR (1990) "Serotonin (5-HT) receptors", in Comprehensive Medicinal Chemistry (Ed Emmett JC) Vol 3 567-600 Pergamon Press.
57. Hibert MF Trumpp-Kallmeyer S Bruinvels A and Hoflack J (1991) Mol Pharmacol 40 8-15.
58. Hibert MF Trumpp-Kallmeyer S Bruinvels AT and Hoflack J (1991a) Therapie 46 445-451.
59. Hibert MF Hoflack J Trumpp-Kallmeyer S and Bruinvels AT (1993) Medicine/Sciences 9 31-40.
60. Hibert MF Trumpp-Kallmeyer S Hoflack J and Bruinvels A (1993a) Trends Pharmacol Sci 14 7-12.
61. Hibert M Hoflack J Trumpp-Kallmeyer S Paquet J-L Leppik R Barberis C Mouillac B Chini B and Jard S (1995) Eur J Med Chem 30 189s-199s.
62. Ho BY Karschin A Branchek T Davidson N and Lester HA (1992) FEBS Lett 312 259-262.
63. Hoflack J Trumpp-Kallmeyer S and Hibert M (1993) "Molecular modelling of G protein-coupled receptors"; in 3D QSAR in Drug Design (Ed Kubinyi H) pp 355-372 ESCOM.
64. Höltje H-D and Jendretzki UK (1995) Arch Pharm (Weinheim) 328 577-584.
65. Horn F Weare J Beukers MW Hörsch S Bairoch A Chen W Edvardsen Ø Campagne F and Vriend G (1998) Nucleic Acids Research 26 275-279 [http://www.sander.emblheidelberg.de/ 7tm/].
66. Jansen JM Koehler KF Hedberg MH Johansson AM Hacksell U Nordvall G and Snyder JP (1997) J Chem Inf Comput Sci 37 812-818.
67. Johnson MP Loncharich RJ Baez M and Nelson DL (1994) Mol Pharmacol 45 277-286.
68. Julius D (1991) Annu Rev Neurosci 14 335-360.
69. Kao H-T Adham N Olsen MA Weinshank RL Branchek TA and Hartig PR (1992) FEBS Lett 307 324-328.
70. Kobilka B (1992) Annu Rev Neurosci 15 87-114.
71. Kristiansen K Edvardsen Ø and Dahl SG (1993) Med Chem Res 3 370-385.
72. Kristiansen K and Dahl SG (1996) Eur J Pharmacol 306 195-210.
73. Kristiansen K Dahl SG and Edvardsen Ø (1996) Proteins: Struct Funct Genet 26 81-94 [http://www-grap.fagmed.uit.no/ GRAP/homepage.html].
74. Kuipers W van Wijngaarden I and Ijzerman AP (1994) Drug Des Discovery 11 231-249.
75. Kuipers W van Wijngaarden I Kruse CG Amstel MTHV Tulp MThM and Ijzerman AP (1995) J Med Chem 38 1942-1954.
76. Kuipers W Kruse CG van Wijngaarden I Standaar PJ Tulp M Th M Veldman N Spek AL and Ijzerman AP (1997) J Med Chem 40 300-312.
77. Kuipers W Link R Standaar PJ Stoit AR van Wijngaarden I Leurs R and Ijzerman AP (1997a) Mol Pharmacol 51 889-896.
78. Luo X Zhang D and Weinstein H (1994) Protein Eng 7 1441-1448.
79. Metcalf MA McGuffin RW and Hamblin MW (1992) Biochemical Pharmacology 44 1917-1920.
80. Oksenberg D Marsters SA O'Dowd BF Jin H Havlik S Peroutka SJ and Ashkenazi A (1992) Nature 360 161-163.
81. Oliveira L Paiva ACM and Vriend G (1993) J Computer-Aided Molecular Design 7 649-658.
82. Ostrowski J Kjelsberg MA Caron MG and Lefkowitz RJ (1992) Annu Rev Pharmacol Toxicol 32 167-183.
83. Pardo L Ballesteros JA Osman R and Weinstein H (1992) Proc Natl Acad Sci USA 89 4009-4012.
84. Pardo L Batlle M Duñach M and Weinstein H (1996) J Biomed Sci 3 98-107.
85. Pardo L and Weinstein H (1997) Int J Quant Chem 63 767-780.
86. Parker EM Grisel DA Iben LG and Shapiro RA (1993) J Neurochem 60 380-383.
87. Parker EM Izzarelli DG Lewis-Higgins L Palmer D and Shapiro RA (1996) J Neurochem 67 2096-2103.
88. Peitsch MC (1996) Biochem Soc Trans 24 274-279 [http:// www.expasy.ch/swissmod/SWISS-MODEL.html].
89. Peroutka SJ (1988) Annu Rev Neurosci 11 45-60.
90. Peroutka SJ (1994) Synapse 18 241-260.
91. Rens-Domiano S and Hamm HE (1995) FASEB J 9 1059-1066.
92. Rippmann F and Boettcher H (1993) 7TM 1.
93. Rippmann F (1994) 7TM 4.
94. Rippmann F (1996) "Pride and prejudice and G protein-coupled receptor models" in Membrane Protein Models (Ed Findlay JBC) pp. 91-104 Bios Scientific Publishing.
95. Roth BL Choudhary MS and Craigo S (1993) Med Chem Res 3 297-305.
96. Roth BL Choudhary MS Khan N and Uluer AZ (1997) J Pharmacol Exp Ther 280 576-583.
97. Roth BL Shoham M Choudhary MS and Khan N (1997a) Mol Pharmacol 52 259-266.
98. Saxena PR (1995) Pharmac Ther 66 339-368.
99. Sehertler GFX Villa C and Henderson R (1993) Nature 362 770-772.
100. Sehertler GFX and Hargrave PA (1995) Proc Nat/Acad Sci USA 92 11578-11582.
101. Sealfon SC Chi L Ebersole BJ Rodic V Zhang D Ballesteros JA and Weinstein H (1995) J Biol Chem 270 16683-16688.
102. Shih JC Yang W Chen K and Gallaher T (1991) Pharmacol Biochem Behavior 40 1053-1058.
103. Smolyar A and Osman R (1993) Mol Pharmacol 44 882-885.
104. Spedding M Newman-Tancredi A Millan MJ Dacquet C Michel AN Jacoby E Vickery B and Tallentire D (1998) Neuropharmacology 37 769-780.
105. Strader CD Sigal IS and Dixon RAF (1989) FASEB J 3 1825-1832.
106. Sylte I Edvardsen Ø and Dahl SG (1993) Protein Eng 6 691-700.
107. Sylte I Edvardsen Ø and Dahl SG (1996) Protein Eng 9 149-160.
108. Sylte I Chilmonezyk Z Dahl SG Cybulski J and Edvardsen Ø (1997) J Pharm Pharmacol 49 698-705.
109. Teitler M and Herrick-Davis K (1994) Critical Rev Neurobiol 8 175-188.
110. Trumpp-Kallmeyer S Bruinvels A Hoflack J and Hibert M (1991) Neurochem Int 19 397-406.
111. Trumpp-Kallmeyer S Hoflack J Bruinvels A and Hibert M (1992) J Med Chain 35 3448-3462.
112. Unger VM and Schertler GFX (1995) Biophys J 68 1776-1786.
113. Unger VM Hargrave PA Baldwin JM and Schertler GFX (1997) Nature 389 203-206.
114. Vriend G (1993) 7TM 3.
115. Wang CD Gallaher TK and Shih JC (1993) Mol Pharmacol 43 931-940.
116. Weinstein H and Osman R (1990) Neitropsychopharmacologv 3 397-409.
117. Weinstein H Zhang D and Ballesteros JA (1994) "Hallucinogens acting at 5-HT receptores: toward a mechanistic understanding at atomic resolution"; in Hallucinogens: An Update pp 241-262 US Government Print Office.
118. Westkaemper RB and Glennon RA (1991) Pharmacol Biochem Behavior 40 1019-1031.
119. Westkaemper RB and Glennon RA (1993) Med Chem Res 3 317-334.
120. 2 receptors";in Hallucinogens: An Update pp 263-283 US Government Print Office.
121. Zhang D and Weinstein H (1993) J Med Chem 36 934-938.
122. Zhang D and Weinstein H (1993a) Med Chem Res 3 357-369.
123. Zifa E and Fillion G (1992) Pharmacol Rev 44 401-458.